Whitehawk Therapeutics (NASDAQ:WHWK) Posts Earnings Results, Beats Estimates By $0.10 EPS

Whitehawk Therapeutics (NASDAQ:WHWK) issued its quarterly earnings results on Thursday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10, Zacks reports.

Whitehawk Therapeutics Price Performance

WHWK stock traded up $0.63 during midday trading on Thursday, hitting $4.70. 308,563 shares of the stock traded hands, compared to its average volume of 431,950. The firm has a market cap of $232.42 million, a P/E ratio of -2.80 and a beta of 0.76. The stock’s fifty day simple moving average is $4.11 and its 200-day simple moving average is $3.78. Whitehawk Therapeutics has a 1-year low of $1.57 and a 1-year high of $5.49.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Citigroup began coverage on shares of Whitehawk Therapeutics in a report on Thursday, April 16th. They issued an “outperform” rating for the company. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Oppenheimer restated an “outperform” rating and set a $7.00 price target on shares of Whitehawk Therapeutics in a report on Friday, May 8th. Citizens Jmp initiated coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set a “market outperform” rating and a $8.00 price objective on the stock. Finally, B. Riley Financial initiated coverage on Whitehawk Therapeutics in a research note on Thursday, June 25th. They issued a “buy” rating and a $10.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.20.

Hedge Funds Weigh In On Whitehawk Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of WHWK. Orbimed Advisors LLC acquired a new position in Whitehawk Therapeutics during the third quarter worth $7,915,000. Acuta Capital Partners LLC acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at $6,480,000. KVP Capital Advisors LP acquired a new position in Whitehawk Therapeutics during the 4th quarter worth about $5,242,000. Yu Fan purchased a new position in Whitehawk Therapeutics during the 3rd quarter valued at about $3,933,000. Finally, Vanguard Group Inc. purchased a new stake in Whitehawk Therapeutics during the 3rd quarter worth approximately $2,552,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.